1. Home
  2. SNTI vs SFHG Comparison

SNTI vs SFHG Comparison

Compare SNTI & SFHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.34

Market Cap

10.4M

Sector

Health Care

ML Signal

HOLD

Logo Samfine Creation Holdings Group Limited Ordinary Share

SFHG

Samfine Creation Holdings Group Limited Ordinary Share

HOLD

Current Price

$2.30

Market Cap

9.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNTI
SFHG
Founded
2016
1993
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Publishing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
10.4M
9.5M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
SNTI
SFHG
Price
$0.34
$2.30
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
127.0K
17.1K
Earning Date
05-06-2026
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
77.31
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.32
52 Week High
$2.88
$3.17

Technical Indicators

Market Signals
Indicator
SNTI
SFHG
Relative Strength Index (RSI) 42.48 N/A
Support Level $0.29 N/A
Resistance Level $0.40 N/A
Average True Range (ATR) 0.02 0.00
MACD 0.01 0.00
Stochastic Oscillator 45.39 0.00

Price Performance

Historical Comparison
SNTI
SFHG

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

About SFHG Samfine Creation Holdings Group Limited Ordinary Share

Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.

Share on Social Networks: